![]() |
|
|
Vol. 293, Issue 3, 1106-1111, June 2000
Pharmaceutical Products Division, Department of Integrative
Pharmacology and Gastroenterology Venture, Abbott Laboratories,
Abbott Park, Illinois
ABT-229
(8,9-anhydro-4"-deoxy-3'-N-desmethyl-3'-N-ethylerythromycin
B-6,9-hemiacetal), a synthetic derivative of erythromycin (ERY) with no
antibiotic activity, has been shown to bind to motilin receptors and
stimulate contractile activity of the antrum and small intestine. The
objective of this study was to determine the effect of ABT-229 on
canine gastric emptying (GE) and contractile activity of the antrum and
duodenum in response to a solid meal. Six beagles were used to
determine GE of a solid meal and contractile activity in response to
either vehicle, ABT-229 (0.17, 0.83, 2.5, or 5.0 µg/kg/min), ERY
(33.3 µg/kg/min), or cisapride (CIS) (10 µg/kg/min). Lag
(tlag), half-emptying
(t1/2), and complete emptying (tfull) times were determined. Contractile
data were analyzed for motility index and gastroduodenal coordination.
Compared with vehicle, ABT-229 dose dependently accelerated GE,
tlag was decreased at the two highest doses,
t1/2 was decreased compared with vehicle at
the three highest doses, and tfull was
decreased at all doses compared with vehicle. ERY also decreased
t1/2 and tfull,
whereas CIS decreased all GE parameters. The slopes of the linear phase of GE curves for all drugs and doses were greater than those for vehicle. ABT-229 dose dependently increased the motility index as well
as gastroduodenal coordination. ABT-229 (two highest doses) and CIS
accelerated GE of a solid meal by decreasing the lag phase and
increasing the rate of GE, whereas ERY only increased the rate of GE.
The data suggest that ABT-229 is 7- to 40-fold more potent than ERY in
accelerating GE.
This article has been cited by other articles:
![]() |
D. L. Anderson, F. D. Bartholomeusz, I. D. Kirkwood, B. E. Chatterton, G. Summersides, S. Penglis, T. Kuchel, and L. Sansom Liquid Gastric Emptying in the Pig: Effect of Concentration of Inhaled Isoflurane J. Nucl. Med., July 1, 2002; 43(7): 968 - 971. [Abstract] [Full Text] [PDF] |
||||